Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.

被引：1
|
作者：
Hwang, Inhwang
Kang, Jihoon
Yoo, Changhoon
Kim, Kyu-Pyo
Jeong, Jae Ho
Chang, Heung-Moon
Ryoo, Baek-Yeol
机构：
[1] Univ Ulsan, Asan Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.354
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
354
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis
    Lee, K.
    Hwang, I.
    Kang, J.
    Yoo, C.
    Kim, K-P.
    Jeong, J. H.
    Chang, H-M.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [3] Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
    Di Costanzo, Francesco
    Di Costanzo, Federica
    Antonuzzo, Lorenzo
    Mazza, Ernesto
    Giommoni, Elisa
    CANCERS, 2023, 15 (02)
  • [4] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [5] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [6] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
    Hatashima, Alycia
    Arango, Matthew J.
    Reardon, Joshua
    Freeman, Tracelyn
    Williams, Terence
    McLaughlin, Eric M.
    Abushahin, Laith
    FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
  • [7] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Junko Tahara
    Kyoko Shimizu
    Nao Otsuka
    Junichi Akao
    Yukiko Takayama
    Katsutoshi Tokushige
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 245 - 250
  • [8] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Tahara, Junko
    Shimizu, Kyoko
    Otsuka, Nao
    Akao, Junichi
    Takayama, Yukiko
    Tokushige, Katsutoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 245 - 250
  • [9] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Han, Sung Yong
    Kim, Dong Uk
    Seol, Young Mi
    Kim, Suk
    Lee, Nam Kyung
    Hong, Seung Baek
    Seo, Hyung-Il
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (17) : 3718 - 3729
  • [10] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Sung Yong Han
    Dong Uk Kim
    Young Mi Seol
    Suk Kim
    Nam Kyung Lee
    Seung Baek Hong
    Hyung-Il Seo
    World Journal of Clinical Cases, 2020, (17) : 3718 - 3729
12345